Neutral
Spyre Therapeutics (SYRE) has introduced exclusive forum provisions requiring internal corporate and fiduciary duty claims to be heard in Delaware and...
Bearish
Cameron Turtle, CEO of Spyre Therapeutics Inc (SYRE), sold 15,000 shares of the company on May 1, 2026, increasing his total insider sells over the pa...
Bearish
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows sold 12,500 shares of the company's stock on May 1st for a total of $892,125. This sale reduced his...
Neutral
An insider at Spyre Therapeutics (NASDAQ:SYRE), Sheldon Sloan, sold 78,333 shares of the company's stock on May 1st for a total of $5,600,809.50, exec...
Neutral
Spyre Therapeutics successfully completed a stock offering, raising approximately $463.5 million in gross proceeds. The capital will be used to advanc...